[24] Comparison of diferent microbiological procedures for the diagnosis of Pneumocystis jirovecii pneumonia on bronchoalveolar-lavage fuid L. Franconi, A. Leonildi, et al. BMC Microbiol. May 2022. doi:10.1186/s12866-022-02559-1

[23] DOSAGGIO DEL β-D-GLUCANO SU SIERO DUE METODI A CONFRONTO D. Cirasola, M. Calabro, E. Cavedoni, et al. (2024)

[22] VALUTAZIONE FUNGIXPERT® ASPERGILLUS GALACTOMANNAN DETECTION KIT PER IL DOSAGGIO DEL GALATTOMANNANO NEL SIERO E NEL BRONCOLAVAGGIO M. Calabrò, E. Cavedoni, D. Cirasola, et al. (2024)

[21] Performance of FungiXpert® Aspergillus Galactomannan Detection Kit (CLIA) on bronchoalveolar lavage fluid (BALF). (2023) ECCMID

[20] Diagnostic Laboratory Features and Performance of an Aspergillus IgG Lateral Flow Assay in a Chronic Pulmonary Aspergillosis Cohort. (2023) American Society for Microbiology

[19] CONFRONTO DI DIVERSE METODICHE PER LA DIAGNOSI DI POLMONITE DA PNEUMOCYSTIS JIROVECII IN CAMPIONI DI LAVAGGIO BRONOCOALVEOLARE R. Fais, I. Franconi, A. Leonildi, et al. (2022)

[18] Analytical Performance Evaluation of Goldstream Fungus (1-3)-β-D Glucan.So MK, Huh J, Lee M, Kim SK. Clin Lab. 2022 May 1;68(5). doi: 10.7754/Clin.Lab.2021.210912. PMID: 35536073.

[17] Evaluation of a Cryptococcus capsular polysaccharide detection FungiXpert LFA(lateral flow assay) for the rapid diagnosis of Cryptococcosis. Liu Y, Kang M, Wu SY, Wu LJ, et al. Medical Mycology, Volume 60, Issue 4, April 2022, myac020

[16] Neglecting Genetic Diversity Hinders Timely Diagnosis of Cryptococcus Infections. Shi D, Haas P J, Boekhout T, et al. Neglecting genetic diversity hinders timely diagnosis of Cryptococcus infections[J]. Journal of Clinical Microbiology, 2021.
[15] Evaluation of Carbapenem-Resistant K.N.I.V.O. Detection K-Set for the rapid detection of carbapenemases among carbapenem-resistant gram-negative bacilli. Session: 4. Diagnostic microbiology Category: 4a. Diagnostic bacteriology – culture based and general microbiology, from ECCMID 2022

[14] VALUTAZIONE DI DUE METODICHE PER IL DOSAGGIO SIERICO DEL 1,3-β-D-GLUCANO IN PAZIENTI A RISCHIO DI INFEZIONI FUNGINE INVASIVE. Cipriani R., Brossa S., Zanotto E. et al. (2017)

[13] VALUTAZIONE DI UN NUOVO TEST GOLDSTREAM FUNGUS (1,3)-ß-D-Glucano PER LA DIAGNOSTICA DELLE INFEZIONI FUNGINE INVASIVE. De Nittis R., Delli Carri V., Trecca A. et al. (2017)

[12] Diagnostic performance of the (1-3)-β-D-glucan assay in patients with Pneumocystis jirovecii compared with those with candidiasis, aspergillosis, mucormycosis, and tuberculosis, and healthy volunteers. Son H J, Sung H, Park S Y, et al., (2017), PLoS One. 2017 Nov 30;12(11):e0188860. 

[11] Diagnostic Performance of the (1–3)-β-D-Glucan Assay in Pneumocystitis jirovecii, Invasive Aspergillosis, Mucormycosis, Tuberculosis and Healthy Volunteers. Son H J, Sung H, Park S Y, et al., (2016), Open Forum Infectious Diseases. Oxford University Press, 3(suppl 1): 1562.

[10] Statistical assessment of Tachypleus amoebocyte lysate for early diagnosis of invasive fungal disease at an ICU in China. Qin, Z., Y Ji., Zhang, A., D., LI, J., Liu, D., Wang, Z., Y., Wang, C., X. (2016) ECCMID

[9] Emergence of TR46/Y121F/T289A in an Aspergillus fumigatus Isolate from a Chinese Patient. Chen Y, Wang H, Lu Z, et al., (2015), Antimicrobial Agents & Chemotherapy, 59(11):7148.

[8] Serum Levels of Lipopolysaccharide and 1, 3-β-D-Glucan Refer to the Severity in Patients with Crohn’s Disease. Guo Y, Zhou G, He C, et al., (2015), Mediators of inflammation

[7] The screening performance of serum 1, 3-beta-D-glucan in patients with invasive fungal diseases: a meta-analysis of prospective cohort studies. Hou, T., Y., Wang, S., H., Liang, S., X., Jiang, W., X., Luo, D., D., Huang, D., H, (2015) PLoS ONE 10(7): e0131602.

[6] Platelet parameters and (1, 3)-β -D-glucan as a diagnostic and prognostic marker of invasive fungal disease in preterm infants. Zhao, D., Y., Qiu, G., Luo, Z., C., Zhang, Y., J. (2015). PLoS ONE 10(4): e0123907.

[5] Evaluation of a novel plasma (1, 3)-β-d-glucan detection assay for diagnosis of candidemia in pediatric patients. Liu, Y., Chen, F., Zhu, X., Shen, L., & Zhang, S. X. (2015). Journal of Clinical Microbiology, 53(9), 3017-3020.

[4] The serum glucan level and pathological changes of antifungal treatment for lower respiratory tract infection of Candida albicans. Xu W M, Shui W, Lin J C, et al. Medical mycology, (2014): myu068.

[3] Risk factors for recurrence of invasive fungal infection during secondary antifungal prophylaxis in allogeneic hematopoietic stem cell transplant recipients. Liu F, Wu T, Wang J B, et al., (2013), Transplant Infectious Disease, 15(3): 243-250.

[2] Laboratory diagnosis of invasive aspergillosis: from diagnosis to prediction of outcome. Barton, R., C. (2013) Scientifica

[1] Diagnostic accuracy of serum 1, 3-β-d-glucan for pneumocystis jiroveci pneumonia, invasive candidiasis, and invasive aspergillosis: systematic review and meta-analysis. Onishi, A., Sugiyama, D., Kogata, Y., Saegusa, J., Sugimoto, T., & Kawano, S., et al. (2012) Journal of Clinical Microbiology, 50(1), 7-15.